MVX-ONCO-1: Encapsulation cell therapy for cancer immunotherapy: First in Man Clinical Study

• Forschungsstelle: INNOSUISSE
• Projektnummer: 13952.1 PFLS-LS
• Projekttitel Englisch: MVX-ONCO-1: Encapsulation cell therapy for cancer immunotherapy: First in Man Clinical Study

Kurzbeschreibung (Deutsch)

MVX-ONCO-1: Encapsulation cell therapy for cancer immunotherapy: First in Man Clinical Study

Kurzbeschreibung (Englisch)

MVX-ONCO-1: Encapsulation cell therapy for cancer immunotherapy: First in Man Clinical Study

Abstract (Deutsch)

MaxiVAX SA, in collaboration with HUG and EPFL, has developed a novel, patient-specific, cell-based|immunotherapy, combining irradiated cancer cells and biocompatible capsules containing a cell line|producing a strong immune-stimulator. In May 2011, MaxiVAX¿ innovative immunization approach was|classified as an Advanced Therapeutic Product by the European Medicines Agency. The project is now|under regulatory review by SwissMedic and it expected that a first-in-man study in 15 patients can begin in|Q1-2012 with the infrastructure fully in place at the Cell Therapy Center at the HUG. This work provides an|essential milestone for the further validation development of effective novel anti-cancer therapies.

Abstract (Englisch)

MaxiVAX SA, in collaboration with HUG and EPFL, has developed a novel, patient-specific, cell-based|immunotherapy, combining irradiated cancer cells and biocompatible capsules containing a cell line|producing a strong immune-stimulator. In May 2011, MaxiVAX¿ innovative immunization approach was|classified as an Advanced Therapeutic Product by the European Medicines Agency. The project is now|under regulatory review by SwissMedic and it expected that a first-in-man study in 15 patients can begin in|Q1-2012 with the infrastructure fully in place at the Cell Therapy Center at the HUG. This work provides an|essential milestone for the further validation development of effective novel anti-cancer therapies.